|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||50.26 - 50.82|
|52-week range||50.26 - 50.82|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||N/A|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.30|
NEW YORK, November 28, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care & U.S. President; and Navin Katyal, U.S. Commercial and Global Business Lead for mRNA Portfolio, at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials NEW HAVEN, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced initial results from the Phase 2 cohort expansion portion (VERITAC) of a phase 1/2 study with ARV-471,
Hundreds of Americans die each day from COVID — and the unvaccinated make up a majority of those dead and hospitalized.